Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Placebo of vildagliptin
Drug: vildagliptin
Drug: Metformin

First Posted Date: 2012-02-07

Last Posted Date: 2020-09-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 2004

Registration Number: NCT01528254

Locations: 🇹🇷
Novartis Investigative Site, Kahramanmaras, Turkey

Characterize the Regional Distribution of [11C] ABP688 in Brain by Positron Emission Tomography (PET)

Phase 1

Completed

Conditions: Depression

Interventions: Drug: ABP688

First Posted Date: 2012-02-07

Last Posted Date: 2020-12-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 42

Registration Number: NCT01528241

Locations: 🇺🇸
Novartis Investigative Site, Pittsburgh, Pennsylvania, United States

Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,

Phase 2

Completed

Conditions: Non-infectious Panuveitis
Non-infectious Posterior Uveitis
Non-infectious Intermediate Uveitis

Interventions: Drug: LFG316
Drug: Conventional Therapy

First Posted Date: 2012-02-06

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 25

Registration Number: NCT01526889

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)

Phase 3

Completed

Conditions: Advanced NET of Lung Origin
Advanced NET of GI Origin
Neuroendocrine Tumors

Interventions: Drug: Placebo
Drug: Everolimus
Other: Best suportive care (BSC)

First Posted Date: 2012-02-02

Last Posted Date: 2021-08-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 302

Registration Number: NCT01524783

Locations: 🇺🇸
Cedars Sinai Medical Center SC, Los Angeles, California, United States
🇺🇸
Dana Farber Cancer Institute SC, Boston, Massachusetts, United States
🇺🇸
Texas Oncology P A Texas Oncology Amarillo, Dallas, Texas, United States

and more 15 locations

Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection

Phase 2

Completed

Conditions: Malaria

Interventions: Drug: KAE609

First Posted Date: 2012-02-01

Last Posted Date: 2013-05-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 27

Registration Number: NCT01524341

Locations: 🇹🇭
Novartis Investigative Site, Tak, Thailand

Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia (CLL)
Leukaemia, Lymphocytic, Chronic

Interventions: Biological: Ofatumumab
Drug: Bendamustine

First Posted Date: 2012-01-30

Last Posted Date: 2017-01-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 99

Registration Number: NCT01520922

Locations: 🇪🇸
Novartis Investigative Site, Majadahonda (Madrid), Spain

Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Phase 4

Completed

Conditions: Pulmonary Infections
Pseudomonas Aeruginosa in Cystic Fibrosis

Interventions: Drug: TBM100

First Posted Date: 2012-01-27

Last Posted Date: 2015-02-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 157

Registration Number: NCT01519661

Locations: 🇪🇸
Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain

Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both Medications

Phase 4

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Vildagliptin/ Metformin
Drug: Liraglutide
Drug: Metformin

First Posted Date: 2012-01-25

Last Posted Date: 2017-02-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 62

Registration Number: NCT01518101

Locations: 🇩🇪
Novartis Investigative Site, Völlkingen, Germany

Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib

Phase 4

Completed

Conditions: Metastatic Renal Cell Carcinoma (mRCC)

Interventions: Drug: Everolimus (RAD001)

First Posted Date: 2012-01-23

Last Posted Date: 2017-07-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 29

Registration Number: NCT01514448

Locations: 🇩🇪
Novartis Investigative Site, Wolfsburg, Germany

A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome

Phase 3

Completed

Conditions: Familial Chylomicronemia Syndrome (FCS)

Interventions: Drug: LCQ908
Drug: Placebo

First Posted Date: 2012-01-23

Last Posted Date: 2015-06-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 45

Registration Number: NCT01514461

Locations: 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy